ATE277353T1 - Tau als marker für frühe schäden des zentralen nervensystems - Google Patents

Tau als marker für frühe schäden des zentralen nervensystems

Info

Publication number
ATE277353T1
ATE277353T1 AT99968716T AT99968716T ATE277353T1 AT E277353 T1 ATE277353 T1 AT E277353T1 AT 99968716 T AT99968716 T AT 99968716T AT 99968716 T AT99968716 T AT 99968716T AT E277353 T1 ATE277353 T1 AT E277353T1
Authority
AT
Austria
Prior art keywords
tau
marker
nervous system
cns
central nervous
Prior art date
Application number
AT99968716T
Other languages
English (en)
Inventor
Frank Hulstaert
Eugeen Vanmechelen
Hugo Vanderstichele
De Voorde Andre Van
Gool Stefaan Van
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Application granted granted Critical
Publication of ATE277353T1 publication Critical patent/ATE277353T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Devices That Are Associated With Refrigeration Equipment (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
AT99968716T 1998-09-08 1999-09-07 Tau als marker für frühe schäden des zentralen nervensystems ATE277353T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98870190 1998-09-08
PCT/EP1999/006592 WO2000014546A1 (en) 1998-09-08 1999-09-07 Tau as a marker for early cns damage

Publications (1)

Publication Number Publication Date
ATE277353T1 true ATE277353T1 (de) 2004-10-15

Family

ID=8237090

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99968716T ATE277353T1 (de) 1998-09-08 1999-09-07 Tau als marker für frühe schäden des zentralen nervensystems

Country Status (11)

Country Link
EP (1) EP1112500B1 (de)
JP (1) JP4624559B2 (de)
CN (2) CN101046476B (de)
AT (1) ATE277353T1 (de)
AU (1) AU772151B2 (de)
BR (1) BR9913112A (de)
CA (1) CA2340433A1 (de)
DE (1) DE69920487T2 (de)
ES (1) ES2229817T3 (de)
HK (1) HK1040429B (de)
WO (1) WO2000014546A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016655A1 (ja) 2002-08-14 2004-02-26 Mitsubishi Chemical Corporation 中枢性タウ蛋白質特異的抗体
CA2500739A1 (en) 2002-10-09 2004-04-22 Dmi Biosciences, Inc. Diagnosis and monitoring of inflammation, ischemia and appendicitis
WO2008124066A1 (en) 2007-04-05 2008-10-16 The J. David Gladstone Institutes Agents that reduce neuronal overexcitation
CA2733990C (en) 2008-08-11 2018-12-11 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
WO2011032155A2 (en) * 2009-09-14 2011-03-17 Banyan Biomarkers, Inc. Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury
RU2449287C1 (ru) * 2011-03-17 2012-04-27 Государственное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации (ГОУ ВПО СибГМУ Минздравсоцразвития) Способ антенатального прогнозирования последствий перинатальных поражений нервной системы у детей
US20140302532A1 (en) * 2011-04-12 2014-10-09 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
SG10201913370PA (en) 2012-07-03 2020-03-30 Univ Washington Antibodies to tau
KR101582387B1 (ko) * 2013-12-12 2016-01-05 서울대학교산학협력단 뇌전이암 원인종양 진단용 조성물 및 그의 용도
TWI664190B (zh) 2014-06-27 2019-07-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗－ｔａｕ抗體
RU2568914C1 (ru) * 2014-07-31 2015-11-20 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский институт акушерства и педиатрии" Министерства здравоохранения Российской Федерации Способ прогнозирования перинатального поражения цнс у недоношенных новорожденных
JP2020500508A (ja) 2016-10-28 2020-01-16 バンヤン・バイオマーカーズ・インコーポレーテッド ユビキチンｃ末端ヒドロラーゼｌ１（ｕｃｈ−ｌ１）およびグリア線維酸性タンパク質（ｇｆａｐ）に対する抗体および関連する方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008302A1 (en) * 1991-10-25 1993-04-29 Itt Automotive Europe Gmbh Monoclonal antibodies directed against the microtubule-associated protein tau
JP2879975B2 (ja) * 1992-12-14 1999-04-05 エヌ・ブイ・インノジェネティクス・ソシエテ・アノニム 微小管関連タンパク質タウに対するモノクローナル抗体、これらの抗体を分泌するハイブリドーマ、これらのモノクローナル抗体による抗原認識及びこれらの応用
JPH06239899A (ja) * 1993-02-12 1994-08-30 Teijin Ltd ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法
ATE234324T1 (de) * 1994-07-29 2003-03-15 Innogenetics Nv Monoklonale antikörper gegen ein epitop einer gewissen unterklasse oder form von phosphoryliertem tau, hybridome die diese sezernieren,antigenerkennung durch diese antikörper und deren verwendung
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau

Also Published As

Publication number Publication date
BR9913112A (pt) 2001-05-08
HK1040429A1 (en) 2002-06-07
AU5974699A (en) 2000-03-27
JP4624559B2 (ja) 2011-02-02
DE69920487D1 (de) 2004-10-28
ES2229817T3 (es) 2005-04-16
JP2002524740A (ja) 2002-08-06
HK1040429B (en) 2005-08-12
WO2000014546A1 (en) 2000-03-16
CN101046476B (zh) 2013-04-10
CN1325491A (zh) 2001-12-05
AU772151B2 (en) 2004-04-08
EP1112500B1 (de) 2004-09-22
DE69920487T2 (de) 2006-03-09
CN101046476A (zh) 2007-10-03
EP1112500A1 (de) 2001-07-04
CA2340433A1 (en) 2000-03-16

Similar Documents

Publication Publication Date Title
ATE277353T1 (de) Tau als marker für frühe schäden des zentralen nervensystems
ATE310955T1 (de) Zusammensetzungen und verfahren zum nachweis und zur behandlung von mit chemokinrezeptoren verbundenen krankheiten
WO2005020785A3 (en) Discovery of the microorganism that causes the human autoimmune disease, primary biliary cirrhosis
DE69933661D1 (de) Genomische sequenz des 5-lipoxygenase-aktivierenden proteins (flap), polymorphische marker und ihre anwendung in der diagnose von asthma
DE50304023D1 (de) Diagnose von Myokardinfarkt und akutem Koronarsyndrom durch Kombination von Markern
WO2005052592A3 (en) Methods for diagnosis, stratification, and monitoring of alzheimer’s disease
DE60215339D1 (de) Spezifische detektionsmedien für staphylococcus aureus und identifizierungs- und/oder zaehlmethode unter verwendung besagter detektionsmedien
EP1711618A4 (de) Verfahren zum nachweis von mit endometrialer krankheit oder phase assoziierten markern
DE60117592T8 (de) Diagnose von pre-eclampsia
DE69609161D1 (de) Amplifikationsoligonukleotide und sonden für borrelia, die mit lyme kranheit assoziiert sind
GB0512401D0 (en) Method
EP1543331A4 (de) Verfahren zur diagnose von morbus alzheimer
DE69713498D1 (de) Methode zum nachweis übertragbarer spongiformer enzephalopathien
ATE404118T1 (de) System für kontinuierliche leistungstests
BR0014150A (pt) Diagnósticos e terapêuticos para osteoporose
AU2003234549A8 (en) Systems and methods for identifying organ transplant risk
SG159382A1 (en) Effectors of innate immunity
MXPA05008793A (es) Metodos para la prediccion de posibilidad de suicidio durante el tratamiento.
WO2004058051A3 (en) Androgen-regulated genes and uses for diagnosis, prognosis and treatment of prostate neoplastic conditions
BRPI0414365A (pt) composições, reagentes e kits para, e métodos de diagnosticar, monitorar e tratar obesidade e/ou diabetes
WO2003087761A3 (en) Molecular profiling of disease and therapeutic response using phospho-specific antibodies
ATE366260T1 (de) Kalzium-aktivierte kaliumkanäle mit niedriger und mittlerer leitfähigkeit und ihre verwendungen.
WO2003104763A3 (en) Apparatus and method for relative or quantitative comparison of multiple samples
WO2001038581A3 (en) Vigilance nucleic acids and related diagnostic, screening and therapeutic methods
ATE432996T1 (de) Verfahren zur bestimmung des bodenzustands

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties